GSA Capital Partners LLP Boosts Holdings in MacroGenics, Inc. $MGNX

GSA Capital Partners LLP boosted its position in MacroGenics, Inc. (NASDAQ:MGNX) by 740.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 511,004 shares of the biopharmaceutical company’s stock after purchasing an additional 450,203 shares during the quarter. GSA Capital Partners LLP’s holdings in MacroGenics were worth $823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd purchased a new stake in MacroGenics in the 4th quarter worth approximately $26,000. SG Americas Securities LLC lifted its stake in MacroGenics by 55.9% in the 3rd quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 6,161 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in MacroGenics in the 3rd quarter worth approximately $38,000. Engineers Gate Manager LP purchased a new stake in MacroGenics in the 2nd quarter worth approximately $28,000. Finally, Walleye Capital LLC purchased a new stake in MacroGenics in the 2nd quarter worth approximately $30,000. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Stock Performance

MacroGenics stock opened at $4.53 on Friday. The firm’s fifty day moving average price is $3.33 and its 200-day moving average price is $2.26. The stock has a market cap of $287.93 million, a P/E ratio of -4.12 and a beta of 1.08. MacroGenics, Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $4.64.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.01). The company had revenue of $20.78 million for the quarter, compared to analysts’ expectations of $15.24 million. MacroGenics had a negative net margin of 44.79% and a negative return on equity of 147.80%. On average, analysts predict that MacroGenics, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MGNX. Citigroup reiterated a “market perform” rating on shares of MacroGenics in a research note on Tuesday, February 24th. B. Riley Financial upgraded shares of MacroGenics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $3.00 to $9.00 in a research note on Friday, April 10th. Wall Street Zen upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of MacroGenics in a research report on Friday, May 8th. Finally, Barclays raised their price objective on shares of MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MacroGenics presently has an average rating of “Hold” and an average target price of $5.50.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.